Palisade Bio Inc

Stock Chart, Company Information, and Scan Results

$1.92(as of Jan 6, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Palisade Bio Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$1.92
Ticker SymbolPALI
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees8
CountyUSA
Market Cap$313.3M

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor that is in phase 1a/b clinical trial for the treatment of ulcerative colitis, as well as under phase 1a clinical trial for the treatment of fibrostenotic crohn's disease. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company is headquartered in Carlsbad, California.

Palisade Bio Inc In Our Stock Scanner

As of Jan 07, 2026
As of ---
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.